Sullivan Lara
Known title: Chief Executive OfficerCIK: 0001769457
Associated companies
Transaction History
| PYXS | ▼ Sell | Open Market | 8,541 | $18K | 9/18/2023 | View on chart |
| PYXS | ▼ Sell | Open Market | 100 | $225 | 9/14/2023 | View on chart |
| PYXS | ▼ Sell | Open Market | 3,000 | $7K | 9/13/2023 | View on chart |
| PYXS | ▼ Sell | Tax Withholding | 184,742 | $394K | 9/13/2023 | View on chart |
| PYXS | ▼ Sell | Open Market | 4,917 | $11K | 9/12/2023 | View on chart |
| PYXS | ▼ Sell | Open Market | 20,000 | $45K | 9/11/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 469,483 | $0 | 9/7/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 703,379 | $0 | 3/24/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 95,684 | $0 | 1/3/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 315,273 | $0 | 4/14/2022 | View on chart |
| PYXS | ▲ Buy | Grant | 742,574 | $0 | 3/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops
Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops. Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.